BY MARKETWIRE
-
Eli Lilly’s obesity data is in the top 25 most important events this year, says Citi
In total amount, Eli Lilly will launch information from as much as 9 Stage 3 researches with the GLP-1 tablet computer orforglipron.
-
Morgan Stanley raises price targets of Amplifon and Demant
Morgan Stanley’s quotes for Demant’s incomes prior to passion and tax obligation (EBIT) are 4% over agreement.
-
Novo’s disappointing cagrisema data could give Eli Lilly the upper hand
The recent cagrisema results suggest that Novo Nordisk’s next weight-loss drug is unlikely to differ significantly from Eli Lilly’s Zepbound, according to Bloomberg Intelligence.
-
Ambu off to a good start but share price not expected to reach Moon, economist says
Ambu tends to update its assistance, keeps in mind financial investment economic expert Per Hansen.
-
Amplifon solidifies domestic dominance with two new acquisitions
The world’s largest listening to support retailer expands with two acquisitions within the Italian market.
-
Sydbank: Danish companies’ global footprint shields against Trump’s tariff threat
Bavarian Nordic threats being influenced with its Danish manufacturing of vaccinations.
-
Sana Biotechnology soars on strong results with candidate for type 1 diabetes
The United States biotech business’s share cost raised by 160.6% on Wednesday after arise from a brand-new research study.
-
Novo Nordisk significantly expands collaboration with US-based Valo Health
The partnership arrangement, checked in 2023, is being broadened to target the exploration and advancement of approximately 20 brand-new medication prospects.
-
Novo Nordisk significantly expands collaboration with US-based Valo Health
The collaboration agreement, signed in 2023, is being expanded to target the discovery and development of up to 20 new drug candidates.
-
Morgan Stanley raises price targets of Amplifon and Demant
Morgan Stanley’s estimates for Demant’s earnings before interest and tax (EBIT) are 4% above consensus.
